Funding
Funding not disclosed
Founders
Product
Problem
The development of effective cancer therapies is a lengthy and costly process, with high failure rates in clinical trials. Current approaches often address isolated aspects of drug discovery, leading to inefficiencies and a slow pace of innovation.
Solution
Avatrial offers an integrated, end-to-end platform designed to accelerate the discovery and development of personalized cancer treatments. The platform leverages partnerships with healthcare providers to access comprehensive patient sample data, generating multi-omic datasets of exceptional depth and quality. Proprietary machine learning algorithms are trained on these curated datasets to identify novel biomarkers and therapeutic targets. State-of-the-art experimental models are then employed for rapid validation of identified hypotheses and targets, significantly reducing the time and cost associated with traditional drug discovery pipelines.
Target Audience
Avatrial's primary customers are pharmaceutical companies, biotechnology firms, and academic research institutions focused on oncology drug discovery and development.
Features
- Integrated platform encompassing sample acquisition, multi-omic data generation, AI/ML-driven target identification, and experimental validation.
- Access to donor samples and associated clinical data through strategic healthcare partnerships.
- Generation of comprehensive, low-noise multi-omic datasets from patient samples.
- Machine learning algorithms trained on proprietary datasets for novel biomarker and therapeutic target discovery.
- In-house experimental platform utilizing state-of-the-art models for rapid hypothesis testing and target validation.
- Iterative sample-data-hypothesis-validation cycle optimized for speed and cost-efficiency.